Australian biotechnology company AdAlta (ASX:1AD) has expanded the clinical advisory board of its subsidiary AdCella as it prepares to advance a promising new CAR-T cell therapy for solid cancers into further development and clinical testing. …
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 Australian Biotech
Latest Video
New Stories
-
Liberty expands into Asia Pacific life sciences insurance with new tailored offering
March 25, 2026 - - Australian Biotech -
Budget delivers progress, but hundreds of thousands still waiting for access
March 25, 2026 - - Latest News -
To what extent does the system even see itself as bound by external review?
March 25, 2026 - - Latest News -
PBAC agenda reflects increasing number of companies seeking revised recommendations
March 25, 2026 - - Latest News -
Community pharmacies set to expand patient care following Labor re-election in South Australia
March 25, 2026 - - Latest News -
Clarity advances US manufacturing strategy with major copper 64 supply agreement
March 25, 2026 - -
As 'Horizon Europe' winds down, its successor program remains a work in progress
March 25, 2026 - - Latest News